Objective: This study aims to observe the hypotensive effect of compound Qima capsule on various experimental hypertensive rats and the regulation of related vasoactive factors. Methods: The effect of compound Qima capsule on dynamic changes of blood pressure and the levels of calcitonin gene-related peptide (CGRP), nitric oxide (NO) and neuropeptide Y (NPY) in spontaneously hypertensive rats (SHR), the blood pressure and NO concentration in hypertensive rats induced by L-nitroarginine, as well as the blood pressure and the levels of testosterone (T), angiotensin II (AngII) and aldosterone (Ald) in endogenous hypertensive rats induced by testosterone propionate were observed. The changes of blood pressure and the levels of CGRP, NO, NPY, T, AngII and Ald in rats after continuous intragastric administration of compound Qima capsule were detected. Results: Compound Qima capsule significantly reduced the systolic and diastolic blood pressures of SHR rats in conscious state. With the prolonging of medication time, its hypotensive effect gradually decreased and steadily stabilized. At the same time, it increased the contents of CGRP and NO (P<0.05), decreased the level of NPY (P<0.05); reduced the blood pressure of hypertensive rats induced by L-nitroarginine (P<0.01), increased NO content (P<0.01 or P<0.05); reduced blood pressure values in endogenous hypertensive rats induced by testosterone propionate (P<0.01), and decreased the contents of AngII and Ald (P<0.05 or P<0.01). Conclusion: Compound Qima capsule had significant hypotensive effect on various experimental hypertensive rat models. The mechanism was probably related to improvement of endothelial cell function, increasing the contents of CGRP and NO, decreasing NPY levels, inhibiting the secretions of AngII and Ald in blood vessels, and improving water and sodium retention in vivo. © 2020, Chinese Journal of New Drugs Co. Ltd. All right reserved.